Table 1.
Repositioning studies of antidiabetic drugs in the treatment of cancer.
| Antidiabetic drug classes | Drugs | Cancer | Research methods |
|---|---|---|---|
| Biguanides | Liraglutide | Breast cancer [92] | Meta-analysis |
| Colorectal cancer [93] | |||
| Liver cancer [94], [95] | |||
| Pancreatic cancer [96] | |||
| Endometrial cancer [97] | |||
| Lung cancer [98], [99] | |||
| Sulfonylurea | Glyburide | Lung cancer [105] | Animal study |
| Gliclazide | Liver cancer [101] | Case study | |
| GLP-I receptor agonists | liraglutide | Breast cancer [113] | Meta-analysis |
| Prostate cancer [107] | Cell study | ||
| Endometrial cancer [111] | Cell study | ||
| Exendin-4 | Colorectal cancer [108], [109] | Cell/Animal study | |
| Ovarian cancer [110] | Cell study | ||
| Polycystic ovary syndrome [114] | Meta-analysis | ||
| SGLT-2 inhibitors | Canagliflozin | Breast cancer [116] | Cell study |
| Lung cancer [117] | Cell study | ||
| Dapagliflozin | Breast cancer [116] | Cell study | |
| Sitagliptin | Prostate cancer [118] | Retrospective cohort study | |
| DPP4 inhibitors | Linagliptin | Colorectal cancer [122], [124], [125] | Computational/Meta-analysis/Animal study |
| Gastric cancer [123] | Cell study | ||
| Vildagliptin | Colorectal lung metastases [126] | Animal study |